Seagen

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997, and is headquartered in Bothell, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Seagen reports robust Q4 earnings, poised for growth and innovation

Seagen's strong financial performance, focus on key products like ADCETRIS and PADCEV, and strategic investments in R&D position the company for continued growth.
While facing challenges in managing expenses and navigating competitive markets, Seagen's commitment to innovation and pipeline development presents opportunities for future success.
Overall, Seagen's performance in Q4 2022 reflects a company poised for growth, with a clear strategic focus on optimizing its commercial portfolio and advancing clinical programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.  The company was founded in 1997 and is headquartered in Bothell, Washington.

With two new drugs on the market, revenue prospects look bright.

Is It Too Late to Buy Shares of Seattle Genetics?

The FDA grants accelerated nod to Seattle Genetics' (SGEN) Tukysa in combination with Herceptin and Xeloda to treat adults with advanced unresectable metastatic HER2-positive breast cancer.

Seattle Genetics Gets Early FDA Nod for Breast Cancer Drug

Seattle Genetics today announced FDA approval for its drug Tukysa, also known as tucatinib, which fights aggressive breast cancers.

Seattle Genetics gets FDA approval for breast cancer treatment drug Tukysa

Shares of Seattle Genetics Inc. SGEN, +0.21% gained 1.0% in trading on Friday after the Food and Drug Administration approved Tukysa for certain patients with HER2-positive breast cancer when given in combination with chemotherapy.

Seattle Genetics' stock rises on early FDA nod for breast-cancer drug

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

These strong biotech performers are benefiting from impressive drug pipelines rather than speculation about a virus cure.

3 Blue-Chip Biotech Stocks Hitting New Highs

Seattle Genetics (SGEN) may receive an expedited approval pathway for Padcev combo to treat patients with locally advanced/metastatic urothelial cancer in the first-line setting in the United States.

Seattle Genetics Issue Update on Padcev Label Expansion Study

Seattle Genetics: Management's Carefully Laid Plans May Be Coming To Fruition

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock?

Why Is Seattle Genetics (SGEN) Down 3.2% Since Last Earnings Report?

ACADIA Pharma

Amarin Corporation Plc

Exact Sciences

Exelixis

Jazz Pharmaceuticals

Tumultuous market conditions discounted the stock prices of these leading biotech companies.

6 Quality Biotech Stocks on Sale Now

Researchers didn't notice a heightened risk among people who consumed soy milk.

Study Finds Breast Cancer Risk Can Rise by 50% for Women Who Drink a Cup of Milk Every Day

With a new drug on the market and another being reviewed by the FDA, Seattle Genetics’ revenue potential is climbing.

Is Seattle Genetics Stock a Buy?

Patients with HER2-positive breast cancer could have a new treatment option from Seattle Genetics this summer.

Seattle Genetics' Experimental Breast Cancer Drug Receives Priority Review From the FDA

Broadcom

Fastenal

Raytheon

In today’s article I highlight four WEEKLY chart examples of stocks in boxes (trading between price support and price resistance).

4 Stocks Setting Up for Big Price Moves

Merck

Seattle Genetics posted eye-popping data from a study of patients given a combination of Padcev and Keytruda.

Seattle Genetics, Astellas, and Merck Hit a Bladder Cancer Bullseye

Cerner

Mondelez

These lesser-known Nasdaq 100 components could post stronger returns than big tech stocks in the coming months.

3 Nasdaq 100 Stocks With Excellent Upside Potential

Seattle Genetics (SGEN) rides high on Q4 earnings and revenue beat.

Seattle Genetics (SGEN) Q4 Earnings Top, Adcetris Drives Sales

Sales continue to soar for the biotech's lead cancer drug.

Seattle Genetics Smashes Wall Street Estimates in Q4, but Its 2020 Guidance Disappoints

Seattle Genetics, Inc. (SGEN) CEO Clay Siegall on Q4 2019 Results - Earnings Call Transcript

The company beat analyst estimates handily as revenues from royalties, license agreements, and Adcentris sales surged.

Seattle Genetics Reports Q4 Earnings Results

On Thursday, Seattle Genetics reported losses of 14 cents per share on $289.8 million in sales for its fourth quarter ended Dec. 31. In response, SGEN stock skidded in late trading.

This Biotech Giant Just Crushed Fourth-Quarter Sales Forecasts

Seattle Genetics (SGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Seattle Genetics (SGEN) Might Surprise This Earnings Season

Seattle Genetics' (SGEN) Adcetris registers strong sales in 2019. The company wins an accelerated approval for Padcev to treat urothelial cancer while other pipeline candidates also progress well.

Seattle Genetics Up More Than 40% in the Past Year: Here's Why

Axsome Therapeutics

Shares of these biotech companies are near their five-year highs after some strong performances in 2019.

Are Biotech Stocks Due for a Correction in 2020?

Shares of this cancer-focused biotech seem to have "winner" built into their DNA.

Why Seattle Genetics Stock Skyrocketed 102% in 2019

Apple

Avalara Inc

Smartsheet

Microsoft and Amazon are the centerpieces of Seattle’s booming tech scene, and 2019 was a big year for both of them.

News for Seagen Stock (SGEN)